Breast Cancer Female
Conditions
Keywords
breast cancer, statins, abnormal lipid metabolism
Brief summary
In this study, we compared the survival benefit of breast cancer patients with dyslipidemia (low and medium risk of ASCVD). The control group used dietary intervention instead of statins intervention. The main endpoint was 5 years DFS. The subjects were breast cancer patients.
Detailed description
A randomized, open, blank controlled, single-center clinical trial was conducted to compare the survival benefits of statins in breast cancer patients with dyslipidemia (low and medium risk of ASCVD). The control group used dietary intervention instead of statins. The main endpoint was 3 and 5 years DFS. The subjects were breast cancer patients. In this study, 348 patients were randomly divided into two groups according to patients' wishes and written informed consent. The experimental group: control group = 1:1. Subjects were screened and administered continuously until the disease progressed and the toxicity was intolerable. Informed consent was withdrawn or the researcher decided that the drug must be discontinued.
Interventions
DRUGstatins
On the basis of dietary intervention. Simvastatin 20mg/d QN Po (half an hour before bedtime) (dosage can be adjusted according to other indicators of blood lipid level in each review), atorvastatin 10mg/d QN Po (half an hour before bedtime) (patients who can not tolerate the side effects of simvastatin can consider replacing this drug).
BEHAVIORALDietary intervention group (control group)
Restriction of dietary components that increase LDL-C Saturated Fatty Acids Less than 7% of total energy Dietary cholesterol \< 300 mg/d Increasing Dietary Ingredients for Reducing LDL-C Phytosterol 2\ 3 g/d Water soluble dietary fiber 10\ 25 g/d total energy Adjusted to maintain ideal weight or lose weight Physical activity Maintain moderate intensity exercise and consume at least 200 kcal of calories per day
Sponsors
Peking Union Medical College Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
A randomized, open, blank controlled, single-center clinical trial. The control group used dietary intervention instead of statins.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Diagnosed as invasive breast cancer, it has been treated surgically, confirmed by histology, cytology or imaging. 2. Female patients (35-75 years old); 3. The low-risk patients with ASCVD are detailed in Annex 1. 4. Signed written informed consent approved by IRB or IEC
Exclusion criteria
1. The subjects were pregnant or lactating. 2. Pregnancy test positive (urine or serum) in women with potential pregnancy within 7 days before administration. 3. Other invasive tumors (including the second primary breast cancer) may affect the evaluation of outcomes and the compliance of schemes, but subjects who have been cured and survived disease-free for at least five years can be selected. 4. Patients with chronic underlying liver diseases who have abnormal liver function and/or clinical manifestations: Serum total bilirubin \> 2.5 \*ULN; or INR \> 1.5 although there was no increase in bilirubin Serum ALT or AST \> 3 \*ULN; Alkaline phosphatase \> 2.5 \*ULN; Elevated ALT or AST may gradually recover, but with progressively increased fatigue, nausea and vomiting, fever, right upper abdominal pain or tenderness. 5. Extremely high risk ASCVD patients Including acute coronary syndrome (ACS), stable coronary heart disease, revascularization, ischemic cardiomyopathy, ischemic stroke, transient ischemic attack, peripheral atherosclerosis, etc. 6. High-risk ASCVD patients (in accordance with one of the following circumstances): LDL-C\>4.9 mmol/L or TC\>7.2 mmol/L Diabetic patients with 1.8 mmol/L \< LDL-C \< 4.9 mmol/L (or) 3.1 mmol/L \< TC \< 7.2 mmol/L and age \< 40 years The 10-year risk of ASCVD was moderate and younger than 55 years old. The remaining life risk was assessed. Those with any of the following two or more risk factors are defined as high risk: Systolic or diastolic blood pressure (\> 160 mmHg) or (\> 100 mmHg) * Non-HDL-C\>5.2 mmol/L (200 mg/dl) * HDL-C \< 1.0 mmol/L (40 mg/dl) * BMI\>28 kg/m2 Smoking 7. In the abnormal group of simple TG (triglyceride), TG (\> 5.7 mmol/L) 8. Other serious diseases, including: Congestive heart failure (NYHA grade II, III, IV); dyspnea at rest or requiring oxygen therapy; severe infection; uncontrolled diabetes mellitus; 9. If there are serious mental or mental disorders, it is estimated that the subjects'compliance to participate in this study is not strong. 10. Drug allergies to research drugs are known. 11. Participated in other drug clinical trials in the past 30 days. 12. Failure to complete at least one cycle of clinical trials based on this protocol, and failure to evaluate safety and effectiveness. 13. Serious violation of this study program, not in accordance with the prescribed dose, method and course of treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| DFS | 5 years | Disease free survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS | 5 years | Overall survival |
Countries
China
Contacts
Primary ContactXuefei Wang, M.D.
Backup ContactQiang Sun, M.D.
Outcome results
None listed